Literature DB >> 32963012

A mutant form of ERα associated with estrogen insensitivity affects the coupling between ligand binding and coactivator recruitment.

Yin Li1, Laurel A Coons2, René Houtman3, Kathryn E Carlson4, Teresa A Martin4, Christopher G Mayne4,5, Diana Melchers3, Tanner B Jefferson2, J Tyler Ramsey2, John A Katzenellenbogen4, Kenneth S Korach1.   

Abstract

A homozygous missense mutation in the gene encoding the estrogen receptor α (ERα) was previously identified in a female patient with estrogen insensitivity syndrome. We investigated the molecular features underlying the impaired transcriptional response of this mutant (ERα-Q375H) and four other missense mutations at this position designed to query alternative mechanisms. The identity of residue 375 greatly affected the sensitivity of the receptor to agonists without changing the ligand binding affinity. Instead, the mutations caused changes in the affinity of coactivator binding and alterations in the balance of coactivator and corepressor recruitment. Comparisons among the transcriptional regulatory responses of these six ERα genotypes to a set of ER agonists showed that both steric and electrostatic factors contributed to the functional deficits in gene regulatory activity of the mutant ERα proteins. ERα-coregulator peptide binding in vitro and RIME (rapid immunoprecipitation mass spectrometry of endogenous) analysis in cells showed that the degree of functional impairment paralleled changes in receptor-coregulator binding interactions. These findings uncover coupling between ligand binding and coregulator recruitment that affects the potency rather than the efficacy of the receptor response without substantially altering ligand binding affinity. This highlights a molecular mechanism for estrogen insensitivity syndrome involving mutations that perturb a bidirectional allosteric coupling between ligand binding and coregulator binding that determines receptor transcriptional output.
Copyright © 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

Entities:  

Year:  2020        PMID: 32963012      PMCID: PMC7597377          DOI: 10.1126/scisignal.aaw4653

Source DB:  PubMed          Journal:  Sci Signal        ISSN: 1945-0877            Impact factor:   8.192


  61 in total

Review 1.  International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. XXXVIII. Update on terms and symbols in quantitative pharmacology.

Authors:  Richard R Neubig; Michael Spedding; Terry Kenakin; Arthur Christopoulos
Journal:  Pharmacol Rev       Date:  2003-12       Impact factor: 25.468

2.  Scalable molecular dynamics with NAMD.

Authors:  James C Phillips; Rosemary Braun; Wei Wang; James Gumbart; Emad Tajkhorshid; Elizabeth Villa; Christophe Chipot; Robert D Skeel; Laxmikant Kalé; Klaus Schulten
Journal:  J Comput Chem       Date:  2005-12       Impact factor: 3.376

Review 3.  Coregulators in nuclear estrogen receptor action: from concept to therapeutic targeting.

Authors:  Julie M Hall; Donald P McDonnell
Journal:  Mol Interv       Date:  2005-12

4.  Probing the functional link between androgen receptor coactivator and ligand-binding sites in prostate cancer and androgen insensitivity.

Authors:  Bin He; Robert T Gampe; Andrew T Hnat; Jonathan L Faggart; John T Minges; Frank S French; Elizabeth M Wilson
Journal:  J Biol Chem       Date:  2005-12-19       Impact factor: 5.157

5.  Capillarity theory for the fly-casting mechanism.

Authors:  Emmanuel Trizac; Yaakov Levy; Peter G Wolynes
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-28       Impact factor: 11.205

6.  Estrogen receptor subtype-selective ligands: asymmetric synthesis and biological evaluation of cis- and trans-5,11-dialkyl- 5,6,11, 12-tetrahydrochrysenes.

Authors:  M J Meyers; J Sun; K E Carlson; B S Katzenellenbogen; J A Katzenellenbogen
Journal:  J Med Chem       Date:  1999-07-01       Impact factor: 7.446

7.  A frameshift mutation destabilizes androgen receptor messenger RNA in the Tfm mouse.

Authors:  N J Charest; Z X Zhou; D B Lubahn; K L Olsen; E M Wilson; F S French
Journal:  Mol Endocrinol       Date:  1991-04

8.  Org 4333, a potent, irreversibly binding estrogen agonist.

Authors:  A J van den Broek; J Leemhuis; M S de Winter; F J Zeelen
Journal:  Pharm Weekbl Sci       Date:  1983-08-26

9.  All-atom empirical potential for molecular modeling and dynamics studies of proteins.

Authors:  A D MacKerell; D Bashford; M Bellott; R L Dunbrack; J D Evanseck; M J Field; S Fischer; J Gao; H Guo; S Ha; D Joseph-McCarthy; L Kuchnir; K Kuczera; F T Lau; C Mattos; S Michnick; T Ngo; D T Nguyen; B Prodhom; W E Reiher; B Roux; M Schlenkrich; J C Smith; R Stote; J Straub; M Watanabe; J Wiórkiewicz-Kuczera; D Yin; M Karplus
Journal:  J Phys Chem B       Date:  1998-04-30       Impact factor: 2.991

10.  Delayed puberty and estrogen resistance in a woman with estrogen receptor α variant.

Authors:  Samuel D Quaynor; Earl W Stradtman; Hyung-Goo Kim; Yiping Shen; Lynn P Chorich; Derek A Schreihofer; Lawrence C Layman
Journal:  N Engl J Med       Date:  2013-07-11       Impact factor: 91.245

View more
  3 in total

Review 1.  Nuclear Receptor Coregulators in Hormone-Dependent Cancers.

Authors:  Hedieh Jafari; Shahid Hussain; Moray J Campbell
Journal:  Cancers (Basel)       Date:  2022-05-13       Impact factor: 6.575

2.  Role of estrogen receptor coregulators in endocrine resistant breast cancer.

Authors:  Kristin A Altwegg; Ratna K Vadlamudi
Journal:  Explor Target Antitumor Ther       Date:  2021-08-30

Review 3.  The physiological role of estrogen receptor functional domains.

Authors:  Yukitomo Arao; Kenneth S Korach
Journal:  Essays Biochem       Date:  2021-12-17       Impact factor: 8.000

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.